Michael Intrator

Business news, market intelligence, and global industry analysis.

The Latest

Can fewer infusions improve adherence in Fabry disease enzyme replacement therapy?

CVS stock slips as Aetna settles Medicare Advantage diagnosis code fraud case for $117.7m

What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)

CVGI surges 54% as CVG names Zoox strategic supplier and issues $700M revenue outlook for 2026

CoreWeave reopens acquisition talks with Core Scientific after rejected $1.02bn proposal in 2024

CoreWeave (Nasdaq: CRWV) Q4 2025 earnings: AI cloud revenue hits $5bn as 2026 capital spend targets $35bn

CoreWeave CRWV Q4 2025 earnings analysis: $5.1B revenue, $66.8B backlog, $12-13B 2026 guidance. Read what the numbers really mean for AI infrastructure.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

February 27, 2026